title: Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy.
abstract: The ability of trimetazidine (2,3,4, trimethoxybenzylpiperazine dihydrochloride, TMZ) to protect the myocardium against anthracycline (ANT)-induced cardiotoxicity during chemotherapy has been evaluated in female patients with breast cancer. A clinical trial was conducted in 61 patients subdivided into three groups: group 1 (n = 15, G1 ) treated with standard ANT protocol and cardioprotection by dexrazoxane (DEX) plus TMZ (60 mg, daily dose); group 2 (n = 22, G2) treated with ANT and cardioprotection by TMZ only; and group 3 (n = 24, G3) scheduled to receive ANT therapy and DEX. All the patients submitted to an echocardiographic evaluation of diastolic function (E wave velocity, A wave velocity, isovolumetric relaxation time [IVRT], deceleration time [DT]) at enrollment (T0), at T1 time, at T2 time, and at T3 time. After a 12-month follow-up period, the patients showed a good conservation of diastolic function both in G1 and G2 groups. No statistically significant difference was observed in E wave and A wave velocity and E/A ratio after ANT treatment. TMZ produced a cardioprotective effect, comparable to DEX protection, against subacute and chronic subclinical cardiotoxicity with no significant changes in diastolic function after 1 year of follow-up.
authors.affiliation: Department of Clinical Medicine, La Sapienza University of Rome, Italy.
authors.forename: Demetrio
authors.initials: D
authors.lastname: Tallarico
authors.forename: Vito
authors.initials: V
authors.lastname: Rizzo
authors.forename: Fernando
authors.initials: F
authors.lastname: Di Maio
authors.forename: Federica
authors.initials: F
authors.lastname: Petretto
authors.forename: Gianluca
authors.initials: G
authors.lastname: Bianco
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Placanica
authors.forename: Marta
authors.initials: M
authors.lastname: Marziali
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Paravati
authors.forename: Nicolò
authors.initials: N
authors.lastname: Gueli
authors.forename: Fortunato
authors.initials: F
authors.lastname: Meloni
authors.forename: Stefano Villatico
authors.initials: SV
authors.lastname: Campbell
mesh_terms: D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D002317:Cardiovascular Agents / Q000627:therapeutic use; D003971:Diastole / Q000187:drug effects; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D011929:Razoxane / Q000627:therapeutic use; D014292:Trimetazidine / Q000494:pharmacology / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D002317:Cardiovascular Agents; D014665:Vasodilator Agents; D011929:Razoxane; D014292:Trimetazidine